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A B S T R A C T
 
The Retrovirus Epidemiology Donor Study (REDS) program was established in the United 
States in 1989 with the purpose of increasing blood transfusion safety in the context of the 
HIV/AIDS and human T-lymphotropic virus epidemics. REDS and its successor, REDS-II were 
at first conducted in the US, then expanded in 2006 to include international partnerships 
with Brazil and China. In 2011, a third wave of REDS renamed the Recipient Epidemiology 
and Donor Evaluation Study-III (REDS-III) was launched. This seven-year research program 
focuses on both blood banking and transfusion medicine research in the United States 
of America, Brazil, China, and South Africa. The main goal of the international programs 
is to reduce and prevent the transmission of HIV/AIDS and other known and emerging 
infectious agents through transfusion, and to address research questions aimed at 
understanding global issues related to the availability of safe blood. This article describes 
the contribution of REDS-II to transfusion safety in Brazil. Articles published from 2010 to 
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Introduction
Retrovirus Epidemiology Donor Study (REDS) is the name of 
a multicenter transfusion safety research program funded 
by the National Heart, Lung, and Blood Institute (NHLBI) of 
the National Institutes of Health (NIH) in the United States 
of America. A review was recently published about the 
accomplishments of the REDS program, and its successor, 
REDS-II.1
The NHLBI REDS project started in 1989 during the HIV 
epidemic, and had as principal objectives the improvement 
of transfusion safety in the light of retroviral infections. Its 
successor, REDS-II, was launched in 2004 and expanded in 
2006 to include two large international research components 
consisting of partnerships between US Institutions and blood 
center networks in Brazil and China. In 2011, a new 7-year 
program was initiated, the Recipient Epidemiology and Donor 
Evaluation Study-III (REDS-III), which extended the focus 
of REDS and REDS-II to include not only research in blood 
banking (focused on blood donors and their donations) but also 
clinical transfusion research (focused on transfused recipient 
outcomes). REDS-III includes large research collaborative efforts 
conducted in the US, Brazil, China and South Africa. The REDS 
programs have all been structured1 to establish donor and 
donation databases that serve as the basis for conducting 
detailed analyses of blood safety and availability in each 
country, and to conduct specific protocols that directly address 
key research questions in blood safety and transfusion 
medicine in each country.2
In Brazil, the REDS-II project started in three blood 
centers:  Fundação Pró-Sangue  (FPS) in São Paulo,  Fundação 
Hemominas in Belo Horizonte and Fundação Hemope in Recife. 
Later, Hemorio in Rio de Janeiro was also included. The program 
collected and analyzed data from the operational systems 
of the blood centers and from specific research protocols. 
Table 1 summarizes the overall data sources and the studies 
performed in Brazil under the REDS-II program.
Database analyses
Most blood centers in Brazil carry out their operations using 
computerized information systems. However, these systems 
are heterogeneous, so obtaining nationwide data is not an 
easy task. In the Brazilian project, the variables from the US 
REDS program were adapted to the Brazilian context and a 
data warehouse was developed by the Institute of Mathematic 
and Statistics (USP) to receive and validate the data.2 During 
REDS-II, data were transferred to a central data-coordinating 
center. A web application was developed to streamline the 
process, including a system for data management and quality 
control checking for consistency. The development of this tool 
was a major accomplishment as it allows the inclusion of data 
from other centers in Brazil and allows the Brazilian group 
to continue this hemovigilance effort on a larger scale and 
outside of the context of the REDS research programs.
Blood donor characteristics in Brazil
In the initial publication of the Brazilian REDS-II 
project, Carneiro-Proietti  et al.  documented that the 
studied donor population is relatively young with more 
2013 are summarized, including database analyses to characterize blood donors, deferral 
rates, and prevalence, incidence and residual risk of the main blood-borne infections. 
Specific studies were developed to understand donor motivation, the impact of the deferral 
questions, risk factors and molecular surveillance among HIV-positive donors, and the 
natural history of Chagas disease. The purpose of this review is to disseminate the acquired 
knowledge and briefly summarize the findings of the REDS-II studies conducted in Brazil 
as well as to introduce the scope of the REDS-III program that is now in progress and will 
continue through 2018.
© 2014 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. 
All rights reserved. 
 
Studies
 
Goals
Type of 
study
Number of 
subjects
Establishment of 
a Comprehensive 
Donor and 
Donation 
Database
Describe donor 
demographics, 
prevalence and 
residual risk 
of transfusion-
transmitted 
disease
Database 
analysis
1,900,000
The HIV Case-
Control and 
Molecular 
Surveillance 
Study
Describe risk and 
motivation among 
HIV-positive 
donors and 
characterize the 
HIV strains
Case control 1342
Chagas Natural 
History among 
Blood Donors
Describe the 
natural history 
of Chagas among 
positive blood 
donors
Retrospective 
cohort study
1088
Motivation to 
Donate
What motivates 
people to donate 
blood in Brazil?
Cross 
sectional
7635
Deferral study Understand if the 
deferral criteria 
questionnaire 
improves blood 
safety
Cross 
sectional
3933
Table 1 - Sources of data and the studies performed in 
Brazil under the Retrovirus Epidemiology Donor Study II 
(REDS-II) program
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than  60%  below  35  years of age.3 Males are predominant, 
accounting for 66% of the donors; and 39% are replacement 
donors: donors who give either at the request of or on behalf 
of a specific recipient to replace units in the overall supply. 
The average number of donations per donor/year for two years 
was 1.48 at FPS; 1.58 at Hemope, and 1.42 at Hemominas.
The return rates and inter-donation intervals were analyzed 
by Almeida-Neto et al. who showed that 28.8% of first-time 
donors and 56.5% of repeat donors returned to donate within 
two years of initial donation, rates not particularly different 
from those observed in the US.4 Community donors, donors 
who give to the general blood supply, were more likely to 
return than replacement donors;  Hemope had the highest 
return rate.
Currently there are no national policies stipulating 
eligibility criteria for blood donation based on the number of 
sexual partners prior to donation. The three primary REDS-II 
Brazil centers had introduced a question about the number of 
sexual partners in the past year during the donor screening 
procedure. The centers adopted different cut-off points: São 
Paulo – up to six sexual partners; Recife – up to three sexual 
partners; Belo Horizonte – up to two sexual partners in the 
previous year. Patavino  et al.  evaluated the relationship 
between the number of heterosexual partners and infectious 
diseases at the three blood centers listed above.5 A correlation 
was found between the number of heterosexual partners in the 
year previous to the donation and the prevalence of HIV and 
syphilis. These analyses highlight the importance of keeping 
questions related to heterosexual activities in Brazilian blood 
centers as well as provided clues about possible cut-off values 
(or example, FPS has now decreased the deferral rule to a 
maximum of 3 sexual partners in the past year).
Gonçalez et al. analyzed the rates and reasons for deferral in 
each center.6 The centers use different codes and approaches 
for donor deferral so the first step was to group them into 
similar categories. The overall deferral rate was 22.5%; Belo 
Horizonte had the highest rate (27%), followed by Recife (23%) 
and São Paulo (19%). Females were more likely to be deferred 
than males (30% vs. 18%, respectively). The three most common 
deferral reasons were low hematocrit or hemoglobin, medical 
diagnosis, and high-risk behavior. Notably, the types and 
frequencies of deferral varied substantially among the three 
blood centers. The results indicated that blood donor deferral 
in Brazil has regional aspects that should be considered when 
national policies are developed.6 This study also highlighted 
the potential value in standardizing codes and procedures 
among centers.
Gonçalez et al. also reviewed 700,000 whole blood donations 
to assess adverse reactions among blood donors and observed 
an overall reaction rate of 2.2%.7 However, the rates were very 
different in each center: 53, 290, and 381 per 10,000 donations 
in Recife, São Paulo, and Belo Horizonte, respectively. Reactions 
were classified as: mild grade for presyncopal vasovagal 
adverse reactions (VVRs) such as pallor, sweating and anxiety, 
in the majority of situations (95%); 4.6% were considered 
moderate grade for hypotension, vomiting, and transient loss 
of consciousness; and 0.4% were considered severe reactions 
when there is loss of consciousness associated to other signs 
and symptoms such as recurrent vomiting, prolonged pulse 
and/or blood pressure recovery times, incontinence, and 
convulsions, among other signs and symptoms. Females were 
twice as likely to have an adverse reaction as males.
Almeida-Neto et al. conducted an analysis at FPS to assess 
the demographic profile and infection disease markers in 
donors who said their blood should not be used when asked 
at the time of the donation (Confidential Unit Exclusion or 
CUE) process.8 At FPS the policy was to discard all subsequent 
donations from donors who self-excluded their donations 
using the CUE process. A total of 265,550 donations from 
181,418 donors were evaluated and a total of 3.6% of the 
units were discarded – 1.1% by the current CUE, and 2.5% 
due to CUEs in previous donations. Self-excluded donors had 
a tendency to be male, with poor schooling (less than eight 
years), non-Caucasian and first-time donors. Donors who 
selected CUE on the current donation were more likely to a 
have positive infectious disease marker than donors who had 
never selected CUE [Odds ratio (OR) = 1.41; 95% confidence 
interval (CI) 1.13-1.77)], whereas donors who had previously 
used CUE (but not for the current donation) were not more 
likely to have a positive marker than donors who had never 
selected CUE (OR = 1.04; 95% CI: 0.75-1.45). Thus the results 
suggest that discontinuing the ongoing discard of the unit of 
donors who self-excluded in the past but not for the current 
donation should be considered.8
Transfusion related acute lung injury (TRALI) is one of the 
main causes of severe adverse reactions and post-transfusion 
death in recipients. One of the options for Brazilian blood 
centers to mitigate this problem is to use male plasma only 
and/or to defer multiparous female donors from apheresis 
platelet donation. Blatyta et al. analyzed the impact of only 
deferring multiparous females from donating apheresis 
platelets and found that there would be a tolerable 5% decrease 
of all apheresis platelet collections.9 However, 30.8% of whole 
blood plasma and 24.1% of apheresis platelet donations 
would not be available if only male donor plasma was issued 
for transfusion and all female donors were deferred from 
apheresis donation, respectively, suggesting TRALI mitigation 
by selecting only male donor plasma products would have an 
unacceptable impact on plasma and platelet availability.
Prevalence, incidence and residual risk of transfusion 
transmitted disease
The REDS-II dataset enabled us not only to define the 
prevalence, incidence and residual risk of infectious disease, 
but to evaluate the associations between infections and 
donor demographic characteristics.10-13  Table 2 summarizes 
the main findings. HBsAg was the marker with the highest 
prevalence among first time donors. HIV had the lowest 
prevalence among first time donors but in comparison to the 
other markers, the incidence was the highest among repeat 
donors (although it was not possible to define the incidence 
for HBV). São Paulo had the highest prevalence among first 
time donors for Hepatitis C virus (HCV) and Chagas, while 
HIV and human T-lymphotropic virus (HTLV) was higher in 
Recife. The use of parallel blood donor screening for HIV with 
two enzyme immunoassays (EIAs), as is mandatory in Brazil 
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Use of the database to assess the effectiveness of interventions
The ability to collect systematic blood donor data allowed us to 
conduct a trial to evaluate the effectiveness of an educational 
intervention among blood donors. Gonçalez  et al.  assessed 
the impact of an educational brochure in enhancing blood 
donors’ knowledge about the screening test window phase, 
which consists of the time frame after infection when a 
person can transmit HIV through blood donation but still 
has not produced antibodies detectable by serology, reducing 
at-risk individuals from donating.16 This trial compared an 
educational intervention as a blood center’s usual practice. 
A brochure explaining the HIV window, the importance of 
the deferral questions and where the donor could get free 
testing at other sites was distributed in alternating months 
to all donors. After donating, sampled participants completed 
questions about their HIV window period knowledge. 
While the educational pamphlet increased window period 
knowledge, contrary to expectations this information alone 
was not enough to make donors self-defer or acknowledge 
potential behavioral risk. This study highlights the difficulties 
in increasing donor adherence to the screening questionnaire.
Blood recipient outcomes
By linking three databases (blood center donation data, the 
hospital patient records and the National Death Index), 
Gonçalez  et al.  were able to describe recipient survival and 
blood utilization according to patients’ diagnoses at Hospital 
das Clínicas of the Faculdade de Medicina of the Universidade 
de São Paulo.17 Of the 30,799 hospitalized patients in 2004, 
12.4% received blood transfusions. These patients had 
10,479 transfusion episodes, consisting of 39,561 transfused 
components: 42% red blood cells, 40% platelets and 16% 
plasma.
The median number of components transfused was three 
per patient admission. Mortality during hospitalization was 
different for patients whose admissions included transfusion 
than those that did not (24% vs. 4%). After one year, 56% of 
transfusion recipients were alive. The most frequent diagnoses 
in patients who received transfusions were malignant 
neoplasms, diseases of the gastrointestinal (GI) tract, diseases 
of the circulatory system, emergencies, poisoning and other 
external traumatic causes.17
REDS-II Brazil studies
Donor motivation study
During the REDS-II program, a cross sectional study was 
performed in three centers (FPS, Hemope and Hemominas) 
to understand the motivation to donate and social 
capital among blood donors in Brazil. Approximately 7000 
participants completed self-administered questionnaires on 
demographics, social capital, donor motivation, test seeking 
behavior and knowledge about HIV infection. Donors were 
enrolled and completed the survey before the screening 
process. Results showed that the main motivational factors 
identified were altruism (43.5%), direct appeal to donate 
was also reviewed and concluded that parallel testing did not 
appear to improve the ability to capture and interdict HIV-
positive blood donations.14
Inconclusive serological test results for Chagas Disease 
are a major challenge for blood donor counseling in Brazil. 
By using a second recombinant EIA (EIAr) assay, Sabino  et 
al.  classified the inconclusive samples into two groups: low 
reactive Chagas (EIAr positive) and probably other parasite 
infections (EIAr negative).13 The data suggest that a second 
recombinant EIA may be used as a confirmatory assay.
In collaboration with Honduras and the US, T. cruzi  EIA 
signal to cut-off values (S/CO) of the Ortho EIA was 
compared to polymerase chain reaction (PCR) results. PCR was 
not positive among individuals with S/CO below 2, suggesting 
that low-level T. cruzi antibody reactive samples may represent 
seroreversion after parasite clearance.15
  
 
 
 
 
Prevalence 
per 100,000 
1st time 
donations
 
Incidence 
per 100,000 
repeat 
donations
Residual 
risk per 
1,000,000 
persons-
year
Total
   HIV 92.2 22.55 11.3*
   HBsAg+Anti-HBC 289 ND ND
   HCV 191 3.11 5.0
   HTLV 135.2 3.59 5.0
   Chagas 140 0 0
São Paulo
   HIV 84.91 37.49 6.4
   HBsAg+Anti-HBC 213 ND ND
   HCV 287 - -
   HTLV 100.7 1.73 -
   Chagas 206 0 0
Belo Horizonte 
   HIV 70.98 33.36 6.0
   HBsAg+Anti-HBC 270 ND -
   HCV 78 - -
   HTLV 82.7 2.82 -
   Chagas 119 0 0
Recife
   HIV 119.15 43.88 7.8
   HBsAg+Anti-HBC 419 - -
   HCV 131 - -
   HTLV 222.4 7.16 -
   Chagas 60 0 0
HCV: hepatitis C virus; HTLV: human T-lymphotropic virus; ND: no 
data. 
* Ag + Ab IA = immunoassay that detect antigen p24 and anti-HIV. 
Ag: antigen; Ab IA: antibody immunoassay.
Table 2 - Prevalence and incidence of blood-borne 
diseases in blood donors at FPS in São Paulo, 
Hemominas in Belo Horizonte and Hemope in Recife 
from 2007 to 2009.
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(41.7%) and personal interest (29.6%).18 Oliveira et al. analyzed 
the relationship between test seeking behavior and social 
capital.19 Approximately 8.1% of the donors were classified 
as self-disclosed test seekers. Male gender, less schooling 
and lower income was associated significantly with donating 
to obtain test results related to infectious diseases (test 
seeking). Test seekers had more cognitive social capital, which 
means that they had more reciprocity, co-operation, sense of 
belonging and social support. Blood centers in Brazil could 
leverage this finding to better communicate with prospective 
donors in ways that convince them to seek testing at locations 
other than blood banks.
HIV case control study
A case-control study was conducted to understand risks and 
motivations to donate among HIV positive donors. In addition 
to FPS, Hemominas and Hemope, Hemorio participated 
in this study. HIV positive cases were invited to participate 
after being counseled, and a comparison group of infection 
negative controls was invited to participate after donation. All 
responded to a questionnaire in an audio computer-assisted 
structured interview (ACASI) an innovative technology 
that allows more privacy and interview standardization, 
eliminating the potential interviewer bias. All respondents can 
both read text onscreen and listen to pre-recorded questions 
and answer options and then record his/her responses 
using a touch screen and/or keyboard.20 A total of 341 cases 
(107 had recently acquired HIV infection) and 791 controls 
completed all study procedures. The most common HIV risk 
factors in males were sex with HIV positive partners, being an 
intravenous drug user (IVDU) or being a partner of an IVDU. 
Among females, predominant risk factors included sex with 
HIV-positive male partners and unprotected sex with multiple 
partners.20 Remarkably, 13% of controls declared a risk factor 
that would have resulted in deferral had it been disclosed 
during the face-to-face donor eligibility assessment at the 
blood center.21 Thus, ACASI elicited increased disclosure of 
HIV risk factors among blood donors and may be a valuable 
modality of interview to be introduced in Brazilian blood 
banks.21 The REDS-II study also allowed us to characterize 
the HIV subtypes and the primary resistance of HIV-positive 
donors from the three REDS-II Brazilian blood centers and 
the blood center of Rio de Janeiro, in accordance with their 
demographic and exposure risk.22 HIV Subtype B was the most 
prevalent in these centers, however an increased proportion 
of non-B subtypes was observed in later years of the study. 
Resistance mutations were detected in 11.8% of the donors 
with no history of antiretroviral treatment.22
Chagas disease retrospective cohort study
The purpose of this project was to characterize the natural 
history of Chagas disease among seropositive blood donors. 
Approximately 500 T. cruzi seropositive donors from the São 
Paulo (FPS) and Montes Claros (Hemominas) blood centers and 
seronegative controls, who donated between 1996 and 2002, 
were enrolled. This allowed an investigation of rates of Chagas 
cardiac disease. A detailed health history and questionnaire 
was administered to all seropositive and seronegative 
donors and clinical patients and electrocardiograms 
(ECG) and echocardiograms (Echo) were performed to all 
participants. The project used a refined definition of Chagas 
cardiomyopathy: All cases and controls with any abnormality 
in the ECG and Echo found during clinical evaluation were 
blind reviewed by three cardiologists. The rate of false positive 
attribution of Chagas among seronegative controls was 5%. 
Excluding this error, research revealed a moderate annual 
incidence (1.85%) of Chagas cardiomyopathy in seropositive, 
asymptomatic donors.23 Another important finding was 
that the Echo could be performed only on individuals with 
particular ECG abnormalities without losing sensitivity to 
detect the cardiomyopathy cases.
Ribeiro et al. reviewed the ECG results in detail, described 
the most important abnormalities associated with these 
cases and tried to find which ones were most associated 
with decreases in ejection fraction which is today the most 
important parameter to define prognosis of heart disease.24
Donor deferral study
The four REDS-III centers also conducted a study of deferred 
blood donors to assess the effectiveness of donor deferral. 
During the routine eligibility assessment, if a donor was 
deferred for reasons related to higher risk behaviors, the 
donor was invited to participate in a study to assess disease 
marker rates. Samples were collected and screened for all 
infections using the routine procedures of the blood centers. 
In addition, the donors completed an ACASI to further assess 
both disclosed and undisclosed risks. The study successfully 
enrolled 3933 donors who completed all study procedures. 
Preliminary results indicate that donor deferral based on 
questioning donors about higher risk behaviors does prevent 
the acceptance of donors with elevated rates of infectious 
disease markers in Brazil, clearly reducing the risk of 
transfusion-transmitted infection.25
REDS-III studies – new contributions to blood 
safety and transfusion outcomes in Brazil
REDS-III was established in 2011. The structure of REDS-III is 
similar to REDS-II with the same three former blood centers, 
and a fourth additional collaborating center, Hemorio, the 
Blood Center of Rio de Janeiro, contributing donor and 
donation data to a centralized database that matches the 
previous REDS-II database. This will allow for a longer term 
trend analyses of donors and infections over a period of more 
than ten years when completed. In addition specific protocols 
have already been completed or are planned. The following 
studies are currently underway:
1. A study on dengue  with the objective of defining the 
rate of transmission and penetration of the disease in 
both donors and recipients. This study enrolled more 
than 40,000 donors and 1000 recipients during the 2012 
epidemic in Rio de Janeiro and Recife. Analyses of Dengue 
RNA status and immune responses are ongoing as well as 
an assessment of the symptoms of Dengue infection in 
blood recipients.
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2. A longitudinal multicenter study of sickle cell disease 
(SCD) in Brazil with the objective of understanding the 
consequence of transfusion among these patients and 
establishing a large cohort in Brazil. The study plans to 
enroll a large cohort of SCD patients to understand the 
epidemiology of the disease in Brazil and also to assess 
specific questions such as outcomes of transfusion 
in this population, including factors associated with 
alloimmunization of SCD patients and the relationship 
between SCD and HIV infection.
3. An HIV risk factor and molecular surveillance study with 
the objective to monitor the rate of infection and 
epidemiological variants among blood donors in Brazil. 
Using the tools developed for the REDS-II HIV case 
control study, ongoing monitoring of risk behaviors and 
an evaluation of the HIV subtypes and primary drug 
resistance patterns will be conducted.
4. A  donor notification study  to assess success rates in 
blood donor notification following donation test results 
is currently being planned. This study will also seek to 
follow-up donors who have previously tested HIV positive 
to determine the rates of and barriers of access to medical 
care services following a positive HIV test as a result of 
blood bank screening.
Conclusion
The REDS-II program in Brazil was able to establish a 
collaborative research network between four large blood 
banks and created the conditions for the systematic 
analysis of the data generated by these centers. Additionally, 
Brazilian participating centers have further developed strong 
partnerships with researchers from the US and other countries, 
and are developing the expertise in Brazil necessary to the 
establishment and continuation of a research network that 
can serve as an example to other countries. It also established 
the conditions for the development and realization of multi-
center research protocols that address key research priorities 
in blood banking in Brazil. This program has been remarkably 
successful in conducting important research to advance 
blood safety and availability in Brazil. REDS-III will further 
contribute to this body of knowledge with additional studies 
of blood recipients in Brazil.
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